Your quality system is inspection-ready only when your records prove that controlled processes work every day, product risks are managed, and known problems are corrected before they spread. FDA doesn’t issue a simple pass-or-fail grade;…
Biotech due diligence should verify whether the company’s central scientific claim survives independent review and whether the requested capital can reach a defined value-changing milestone. Before funding, you should connect the science, clinical plan, regulatory…
You avoid the wrong FDA regulatory path by classifying the proposed product from its intended use and the means by which it achieves that use, then determining whether multiple regulated constituent parts create a combination…
A CMC package can withstand FDA review when every claim about identity, strength, quality, purity, potency, and stability is supported by traceable data that matches the proposed manufacturing process and development stage. The package weakens…
Your IND is ready when FDA reviewers can trace a defensible line from product quality and nonclinical evidence to the proposed starting dose, clinical safeguards, and sponsor controls. Document volume doesn’t establish readiness; phase-appropriate evidence…
